Pre-exposure Prophylaxis During COVID-19

What Is COVID-19?

The coronavirus disease 2019 (COVID-19) is a communicable illness brought on by the SARS-CoV-2 virus. In December 2019, Wuhan, China, reported the first instance of its kind. The rapid global spread of the illness led to the COVID-19 pandemic.

COVID-19 symptoms usually vary. They frequently include fever, cough, headache, exhaustion, loss of taste and smell, and breathing difficulties. After exposure to the virus, symptoms can appear one to fourteen days later. Around one-third of the individuals who have been infected have not displayed any symptoms at all.

• The majority of individuals experience mild-to-moderate symptoms.

• Mild pneumonia (lung infection).

• About 14 percent experience severe symptoms, such as dyspnea (shortness of breath).

• Hypoxia (decreased oxygen level in tissues).

• Lung involvement of over 50 % on imaging.

• About 5% experience critical symptoms, such as respiratory failure, shock, or multiorgan dysfunction.

• Severe symptoms are more common in older adults.

When the virus particles are inhaled or come into direct contact with the eyes, nose, or mouth, COVID-19 can spread. However, the possibility of getting infected is greater when people are close to one another. The disease can be transmitted if virus-containing aerosols are suspended in the air and people come into contact with such air with suspended particles. Additionally, if a person touches any surface that is contaminated and touches the nose or mouth. The chances of COVID-19 transmission is very high. Some individuals remain asymptomatic but can transmit the virus for 20 days.

Vaccination, remaining at home, putting on a mask in public, avoiding crowded areas, maintaining an appropriate distance from other people, ventilating confined areas, controlling possible exposure durations, regular hand washing with soap and water for at least 20 seconds, maintaining good respiratory hygiene, and refraining from touching the mouth, nose, or eyes with unwashed hands are a few preventative measures to lower the risk of infection.

What Is Pre-exposure Prophylaxis During COVID-19?

Pre-exposure prophylaxis refers to using medication to help build up protection against COVID-19 and lower the risk of developing severe illness or dying from the virus before transmission of the infection from individuals who have it.

Individuals who are 12 years of age or older may be eligible for pre-exposure prophylaxis for the avoidance of COVID-19 if they meet the following requirements:

• Individuals who may not receive a sufficient immunological response from the COVID-19 vaccine due to moderate-to-severe immune dysfunction.

• Individuals who are unable to get the COVID-19 vaccination series due to a medical condition or a severe allergic response to the vaccine or any of its ingredients.

• Individuals should weigh at least 88 pounds (40 kg).

• Do not have COVID-19 infection at the time of pre-exposure prophylaxis.

A potential COVID-19 preventive method could be the administration of PrEP, namely SARS-CoV-2 PrEP, which uses particular antiviral and adjuvant medicines against SARS-CoV-2. Contrary to HIV, for which there is presently no vaccine, SARS-CoV-2 PrEP is likely to be administered to people who do not respond well to vaccination and who are at a high risk of contracting severe COVID-19.

A successful Pre-Exposure Prophylaxis (PrEP) prevents the virus from multiplying in the individual's body, keeping the individual negative for COVID-19. However, if there is no pre-exposure prophylactic strategy, any contact with the virus may result in infection and a positive diagnosis. In such cases, the individual will get an infection, and their immune system will be able to fight against it and help them get better.

Vaccines can prevent COVID-19. The FDA (Food and Drug Administration) has approved the use of Tixagevimab and Cilgavimab as Pre-exposure Prophylaxis (PrEP) against COVID-19 in individuals who were not able to develop an appropriate immune reaction to the vaccine and in those who were not a suitable candidate for the vaccine. The FDA is yet to approve the use of Tixagevimab with Cilgavimab as pre-exposure prophylaxis for COVID-19 due to the rising incidence of omicron subvariants resistant to these drugs.

Who Would Benefit From Pre-exposure Prophylaxis During COVID-19?

Investigators are aware that certain groups of individuals are more prone to suffer severe COVID-19 problems due to worldwide experience with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). Individuals with these factors might benefit from pre-exposure prophylaxis:

• Diabetes and hypertension.

• Being overweight.

• Persistent renal illness.

• Smoke, emphysema, and asthma.

• Heart failure with congestion.

• Cirrhosis of the liver.

• Cancer and immune system inhibition.

• Older than 80 years of age.

Additionally, the possibility of contracting the disease from frequently coming into contact with sick patients is higher for physicians. Specific groups of genes may further increase an individual's vulnerability to COVID-19 infection. These individuals could gain advantages from PrEP medication.

What Are the Drugs That Are Used for Pre-exposure Prophylaxis During COVID-19?

Mefloquine is utilized as a weekly prophylactic. This oral drug is suitable for antiviral prophylaxis that is given weekly because it has a half-life of roughly three weeks and shows promise against SARS-CoV-2. Mefloquine's adverse effects make it a less suitable medication for PrEP.

The antiparasitic medication Ivermectin is an additional choice. In vitro and in vivo, this antibacterial drug with antiviral qualities benefits SARS-CoV-2. Although Ivermectin can be dosed daily or weekly with no side effects, clinical PrEP experiments for COVID-19 have yet to be planned, and the proper antiviral dosage is still up for debate.

A newly discovered antimalarial drug, Tafenoquine, is prescribed for pre-exposure prophylaxis, but due to its adverse effects, it is no longer included in the prophylaxis.

Other drugs include Molnupiravir, Remdesivir, Favipiravir, Tenofovir, Nirmatrelvir, and Azvudine. More research is required to prove the efficacy of these drugs against COVID-19 infections.

Conclusion:

Pre-exposure prophylaxis for COVID-19 is highly recommended for healthcare workers, immunocompromised individuals, and individuals who do not respond to vaccines appropriately. New medications with various benefits could be included in PrEP and help prevent the spread of infection, particularly in highly vulnerable populations. More studies have to be conducted to

check the efficiency of the above-mentioned drugs as preventive measures and as an adjunct to COVID-19 vaccines.